Navigation Links
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Date:9/21/2010

EAST HANOVER, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Novartis Pharmaceuticals Corporation ("Novartis") (NYSE: NVS) announced today that the results of a Phase III study of SOM230 (pasireotide) showed a reduction in cortisol levels in patients with Cushing's disease, a condition in which a benign (non-cancerous) pituitary tumor causes the adrenal glands to produce excess cortisol and can be fatal(1). Results will be presented at the 14th Congress of the European Neuroendocrine Association (ENEA).

At six months, the majority of evaluable patients (91/103) experienced a reduction from baseline in urinary free cortisol (UFC) levels, the main measure of biochemical control of the disease. UFC levels were normalized in 26% of patients randomized to SOM230 900ug twice daily, meeting the primary endpoint of the study. Additionally, median UFC was reduced by 48% in both the 900ug and 600ug dose groups. After 12 months of treatment, results confirmed the durability of the effect(1).

On average, as UFC levels were reduced, clinical symptoms of Cushing's disease improved including reduction of blood pressure, total cholesterol, weight and body mass index (BMI)(1).

Cushing's disease is caused by a benign tumor in the pituitary gland that secretes adrenocorticotropic hormone (ACTH), which triggers the adrenal glands to produce excess cortisol. Cortisol is a powerful steroid hormone that regulates a broad range of physiologic functions, including metabolism and immunity(2). Cushing's disease can cause severe cardiovascular and metabolic-related illnesses or death(3),(4). There are currently no approved medicines to treat Cushing's disease(1).

"There is a critical need for a medical treatment for people with Cushing's disease because currently available options, such as surgery or radiotherapy, are ultimately not effective for many of the patients who suffer from this d
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 27, 2015 The amount Americans ... in 2014 and with growth of 8% will reach ... out of pocket: directly on expenditures, co-pays as part ... and on premiums.  The publisher made its finding in ... the United States . ...
(Date:5/28/2015)... , May 28, 2015  Merck KGaA, ... company for innovative and top-quality high-tech products in ... a global collaboration agreement with the fertility technologies ... advancing fertility science and helping couples create families. ... Germany , a global market leader in ...
(Date:5/28/2015)... May 27, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Proteomics - Technologies, ... This report describes and evaluates the proteomic ... drug discovery, molecular diagnostics and practice of medicine ... of the 21st century. Most commonly used technologies ...
Breaking Medicine Technology:Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 3Merck KGaA, Darmstadt, Germany, as Pioneer in Assisted Reproductive Treatments, Takes Leading Role in Fertility Technologies, Announces a Global Collaboration Agreement with Genea Biomedx 2Merck KGaA, Darmstadt, Germany, as Pioneer in Assisted Reproductive Treatments, Takes Leading Role in Fertility Technologies, Announces a Global Collaboration Agreement with Genea Biomedx 3Merck KGaA, Darmstadt, Germany, as Pioneer in Assisted Reproductive Treatments, Takes Leading Role in Fertility Technologies, Announces a Global Collaboration Agreement with Genea Biomedx 4Global Proteomics Market 2015-2024 - Technologies, Markets and Companies (Updated Edition) 2Global Proteomics Market 2015-2024 - Technologies, Markets and Companies (Updated Edition) 3
... May 12 As recently reported in the North County Times ... helped more than 6.5 million uninsured and financially struggling Americans obtain access to ... to help more patients. , , ... 2.0 " has introduced new online tools that expand community partnerships and enhance ...
... and STOCKHOLM , May 12 A ... for Elekta,s 15th International Leksell Gamma Knife® Society Meeting, which ... ( Athens, Greece ). The most ever submitted in the ... the Elekta website after the meeting. Attendance at ...
Cached Medicine Technology:PPA 2.0 Makes Getting Prescription Assistance Easier 2PPA 2.0 Makes Getting Prescription Assistance Easier 3Gamma Knife Users Share Latest Advances for Treating Cancer, Other Brain Disorders at Society Meeting in Greece 2Gamma Knife Users Share Latest Advances for Treating Cancer, Other Brain Disorders at Society Meeting in Greece 3Gamma Knife Users Share Latest Advances for Treating Cancer, Other Brain Disorders at Society Meeting in Greece 4Gamma Knife Users Share Latest Advances for Treating Cancer, Other Brain Disorders at Society Meeting in Greece 5
(Date:5/28/2015)... May 28, 2015 Altima Technologies, ... Device Library for documenting and diagramming data center ... for the following product lines: , Manufacturer ... 5500, Chatsworth Products N-Series TeraFrame Cabinet, Middle Atlantic ... Eclipse, Fore Systems ForeRunner, Marantz America MM Series, ...
(Date:5/28/2015)... Workers’ compensation costs per claim in Michigan ... study by the Workers Compensation Research Institute (WCRI) ... , The WCRI study, CompScope™ Benchmarks for Michigan, 15th ... days or more of work with those of 16 other ... claim was 4 percent lower than similar claims from 2008. ...
(Date:5/28/2015)... 2015 More than 300 locations of ... money to help the Muscular Dystrophy Association save and ... related life-threatening diseases that limit muscle strength and mobility ... , From June 1 to June 30, sweetFrog associates ... opportunity to help send local children affected by neuromuscular ...
(Date:5/28/2015)... La Mirada, CA (PRWEB) May 28, 2015 ... their Anaheim clinic will now be offering Echocardiography ... examinations will be performed by renowned Qualified Medical ... , The echocardiography test is a non-invasive ... in patients who are critically ill or have ...
(Date:5/28/2015)... Edmond, OK (PRWEB) May 28, 2015 ... pain relief lotion and products, today announced their best-selling lotion ... bottle. Real Time Pain Relief is an FDA registered OTC ... natural and herbal ingredients, such as Aloe Vera, Arnica, Capsicum, ... a low level of Menthol – only 1.25% – to ...
Breaking Medicine News(10 mins):Health News:NetZoom™ Visio® Stencil Library Updates for EMC, Cisco, and Chatsworth Products 2Health News:Michigan Workers’ Compensation Costs Lower Than Most States, Says WCRI Study 2Health News:sweetFrog and MDA Join Forces to Send Kids with Muscle Disease to Summer Camp 2Health News:sweetFrog and MDA Join Forces to Send Kids with Muscle Disease to Summer Camp 3Health News:Healthpointe Is Now Offering Echocardiography Examinations at the Anaheim Clinic. 2Health News:Real Time Pain Relief Introduces New Four Ounce Pump Bottle for their Popular Pain Relief Lotion 2
... 12 Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), ... proprietary product candidates principally,for use in the hospital ... year ended December 31, 2007, and provided corporate ... and for 2008 to date., "During 2007, ...
... by new cases among gay, bisexual men, CDC reports , , ... in a row, rates of syphilis infection have increased in ... bisexual men, according to a new federal report. , "CDC,s ... secondary syphilis -- the earliest and most infectious stages of ...
... novel aerosol version of the most common tuberculosis ... an oral mist, offers significantly better protection against ... dose of the traditional injected vaccine, researchers report ... Academy of Sciences. , The aerosol vaccine -- ...
... SACRAMENTO, Calif., March 12 The following,is being ... Rights:, What:, A consumer advocate will ... loophole in existing law which bars the sharing ... bill, SB 1096,(Calderon), does so by deeming what ...
... 80 years ago, scientist Otto Warburg observed that cancer cells ... normal adult cells. Many decades later, this observation was ... emission technology) imaging. But it has not been known exactly ... it known if this process was essential for tumor growth. ...
... Iowa Department of Pediatrics has been awarded a five-year, ... Health and Human Development, part of the National Institutes ... helps junior faculty members embark on research careers. , ... since 1990 and resulted in the training of 26 ...
Cached Medicine News:Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 2Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 3Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 4Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 5Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 6Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 7Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 8Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 9Health News:Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview 10Health News:U.S. Syphilis Rate Grows for 7th Year in Row 2Health News:U.S. Syphilis Rate Grows for 7th Year in Row 3Health News:Inhaled tuberculosis vaccine more effective than traditional shot 2Health News:Consumer Advocate Speaks Out Against Bill Allowing Invasions of Medical Privacy; Author Received $21k from Bill Benefactors 2Health News:Consumer Advocate Speaks Out Against Bill Allowing Invasions of Medical Privacy; Author Received $21k from Bill Benefactors 3Health News:Consumer Advocate Speaks Out Against Bill Allowing Invasions of Medical Privacy; Author Received $21k from Bill Benefactors 4Health News:Consumer Advocate Speaks Out Against Bill Allowing Invasions of Medical Privacy; Author Received $21k from Bill Benefactors 5Health News:Study helps explain fundamental process of tumor growth 2Health News:Study helps explain fundamental process of tumor growth 3Health News:$2.1 million NIH grant advances U-Iowa child health research 2Health News:$2.1 million NIH grant advances U-Iowa child health research 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: